MInfla-Tilc SIGNED
Generation of therapeutic antibodies targeting type 2 Innate Lymphoid cells in asthma
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0MInfla-Tilc project word cloud
Explore the words cloud of the MInfla-Tilc project. It provides you a very rough idea of what is the project "MInfla-Tilc" about.
Project "MInfla-Tilc" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITE D'AIX MARSEILLE
Organization address contact info |
| Coordinator Country | France [FR] |
| Total cost | 0 € |
| EC max contribution | 150˙000 € (0%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2019-PoC |
| Funding Scheme | ERC-POC-LS |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-01-01 to 2021-06-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITE D'AIX MARSEILLE | FR (Marseille) | coordinator | 150˙000.00 |
Map
Project objective
We are proposing to target Innate Lymphoid Cells 2 (ILC2s), a subset that has been frequently implicated in inflammatory diseases, such as severe asthma. ILC2s are major players in allergic asthma and are abundantly present as tissue resident cells in the lung, both in human and mouse. Strikingly, the induction of allergic asthma in a mouse model deficient in ILC2s is abolished. In addition, the transfer of ILC2s back in the same mouse recapitulates the pathology. Mechanistically, activated ILC2s are the main producer of type 2 cytokines that sustain the chronicity of asthma by recruiting other inflammatory and pathogenic cells, notably eosinophils, and finally drive hyperresponsiveness and mucous hypersecretion. In humans, ILC2s are increased in the peripheral blood mononuclear cells (PBMCs) of patients with allergic asthma compared to healthy controls. They are also found in sputum and PBMCs of patients with severe, eosinophilic asthma compared to mild forms of asthma. Collectively, these data highlight the significance of ILC2s in allergic inflammation and emphasize the idea to target those cells for therapeutic purposes. MInfla-Tilc is a translational and integrated project aiming to launch an innovative therapeutic monoclonal antibody (mAb) treatment against ILC2s to control severe asthma.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MINFLA-TILC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MINFLA-TILC" are provided by the European Opendata Portal: CORDIS opendata.